Epigenetically heterogeneous tumor cells direct collective invasion through filopodia-driven fibronectin micropatterning
Specialized leader cells use stable filopodia to create linear fibronectin tracks to promote collective cancer invasion. Tumor heterogeneity drives disease progression, treatment resistance, and patient relapse, yet remains largely underexplored in invasion and metastasis. Here, we investigated hete...
Saved in:
Published in | Science advances Vol. 6; no. 30; p. eaaz6197 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Association for the Advancement of Science
01.07.2020
|
Subjects | |
Online Access | Get full text |
ISSN | 2375-2548 2375-2548 |
DOI | 10.1126/sciadv.aaz6197 |
Cover
Summary: | Specialized leader cells use stable filopodia to create linear fibronectin tracks to promote collective cancer invasion.
Tumor heterogeneity drives disease progression, treatment resistance, and patient relapse, yet remains largely underexplored in invasion and metastasis. Here, we investigated heterogeneity within collective cancer invasion by integrating DNA methylation and gene expression analysis in rare purified lung cancer leader and follower cells. Our results showed global DNA methylation rewiring in leader cells and revealed the filopodial motor
MYO10
as a critical gene at the intersection of epigenetic heterogeneity and three-dimensional (3D) collective invasion. We further identified JAG1 signaling as a previously unknown upstream activator of
MYO10
expression in leader cells. Using live-cell imaging, we found that MYO10 drives filopodial persistence necessary for micropatterning extracellular fibronectin into linear tracks at the edge of 3D collective invasion exclusively in leaders. Our data fit a model where epigenetic heterogeneity and JAG1 signaling jointly drive collective cancer invasion through MYO10 up-regulation in epigenetically permissive leader cells, which induces filopodia dynamics necessary for linearized fibronectin micropatterning. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Present address: Tempus Labs Inc., Chicago, IL, USA. Present address: Department of Oncology, The University of Texas at Austin, Dell Medical School, Austin, TX, USA. These authors contributed equally to this work. Present address: Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Present address: Wilmot Cancer Institute, Rochester, NY, USA. Present address: Department of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. |
ISSN: | 2375-2548 2375-2548 |
DOI: | 10.1126/sciadv.aaz6197 |